Objectives
Anterior atlanto-axial subluxation (AAS), defined as an anterior atlanto-dental interval (aADI) ≥3 mm, can occur in rheumatoid arthritis (RA) and carries a risk of severe neurological impairments. Our objective was to determine the prevalence and predictors of radiographic aAAS after 12 years’ follow-up of patients with early polyarthritis.
Methods
We studied patients enrolled in the early-polyarthritis cohort ESPOIR between 2002 and 2005 (at least two swollen joints for >6 weeks and <6 months, no other diagnosis than RA, and no previous exposure to glucocorticoids or disease-modifying anti-rheumatic drugs). All patients still in the cohort after 12 years had dynamic cervical-spine radiographs taken then read by two blinded observers. To evaluate how well combinations of tests performed at baseline and 10 years predicted aAAS after 12 years, univariate analysis and multiple logistic regression procedure were applied.
Results
Of 323 patients followed for 12 years, 15 (4.6%; 95% confidence interval: 2.8–6.4) had aAAS. Among baseline variables, only IgA rheumatoid factors were associated (p< 0.05) to aAAS (sensitivity 60%, specificity 75%). Among data collected after 10 years, oral corticosteroid therapy during the 10-year interval, treatment by DMARDs, CRP (mg/dl), and positive tests for RFs were associated with aAAS after 12 years, but only CRP and RFs remained in a model of logistic regression (combination predicted aAAS with a sensitivity of 60% for a specificity of 90%).
Conclusion
In conclusion, the prevalence of aAAS after 12 years was 4.6% in the ESPOIR cohort, with no patients having severe aAAS. Although some factors were found statistically associated to AAS, the event is too rare to allow a clinical relevance.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.